Details of the Drug

General Information of Drug (ID: DMBYCU0)

• Drug Name: Metyrosine
• Synonyms: Demser; Methyltyrosine; Metirosina; Metirosine; Metirosinum; Racemetirosina; Racemetirosine; Racemetirosinum; Metyrosine[USAN]; Racemetirosine [INN]; M 8131; MK 781; Alpha-MPT; Alpha-Methyltyrosine; Demser (TN); H 9/88; L 588357-0; L-AMPT; M-5185; MK-781; Metirosina [INN-Spanish]; Metirosine (INN); Metirosinum [INN-Latin]; Metyrosine (USP); Racemetirosina [INN-Spanish]; Racemetirosinum [INN-Latin]; DL-alpha-Methyltyrosine; L-588357-0; Alpha-Methyl-L-tyrosine; Alpha-Methyl-dl-tyrosine; Alpha-Methyl-p-tyrosine; Alpha-Methyl-para-tyrosine; A-methyl-L-p-tyrosine; Alpha-Methyl-L-P-Tyrosine; Alpha-Methyltyrosine, (L)-Isomer; DL-alpha-Methyl-p-tyrosine; L-alpha-Methyl-p-tyrosine; Alpha-Methyltyrosine, (D,L)-Isomer; DL-2-Methyl-3-(4-hydroxyphenyl)alanine; Alpha-Methyltyrosine, (+,-)-Isomer; L-2-Methyl-3-(4-hydroxy-phenyl)alanine; (+-)-alpha-Methyl-DL-tyrosine; (-)-(S)-2-Amino-3-(4-hydroxyphenyl)-2-methylpropionsaeure; (-)-alpha-Methyl-DL-tyrosine; (-)-alpha-Methyl-L-tyrosine; (2R)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid; (2S)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid; (R,S)-2-Amino-3-(4-hydroxyphenyl)-2-methylpropionsaeure; (S)-alpha-Methyltyrosine; 2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid; 4-Hydroxy-alpha-methylphenylalanine

Indication

Disease Entry	ICD 11	Status	REF
Pheochromocytoma	5A75	Approved	[1]

• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 195.21
  Logarithm of the Partition Coefficient (xlogp); -1.6
  Rotatable Bond Count (rotbonds); 3
  Hydrogen Bond Donor Count (hbonddonor); 3
  Hydrogen Bond Acceptor Count (hbondacc); 4
• ADMET Property:
  Absorption: The drug is well absorbed from the gastrointestinal tract []
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 4: low solubility and low permeability [2]
  Half-life: The concentration or amount of drug in body reduced by one-half in 3.4 - 3.7 hours [3]
• Chemical Identifiers:
  Formula: C10H13NO3
  IUPAC Name: (2S)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid
  Canonical SMILES: C[C@](CC1=CC=C(C=C1)O)(C(=O)O)N
  InChI: InChI=1S/C10H13NO3/c1-10(11,9(13)14)6-7-2-4-8(12)5-3-7/h2-5,12H,6,11H2,1H3,(H,13,14)/t10-/m0/s1
  InChIKey: NHTGHBARYWONDQ-JTQLQIEISA-N
• Cross-matching ID:
  PubChem CID: 441350
  ChEBI ID: CHEBI:6912
  CAS Number: 672-87-7
  DrugBank ID: DB00765
  TTD ID: D0B3QM
  ACDINA ID: D00427

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tyrosine 3-monooxygenase (TH)	TTUHP71	TY3H_HUMAN	Binder	[4]

Molecular Expression Atlas of This Drug

• The Studied Disease: Pheochromocytoma
• ICD Disease Classification: 5A75

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Tyrosine 3-monooxygenase (TH)	DTT	TH	9.10E-04	-2.73	-1.55

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Metyrosine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Metyrosine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[5]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Metyrosine and Lasmiditan.	Migraine [8A80]	[6]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Metyrosine and Thalidomide.	Multiple myeloma [2A83]	[7]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
FD&C blue no. 2	E00446	2723854	Colorant
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Metyrosine 250 mg capsule	250 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6956).
• [2] BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
• [3] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [4] Dopamine beta-hydroxylase deficiency. A genetic disorder of cardiovascular regulation. Hypertension. 1991 Jul;18(1):1-8.
• [5] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [6] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [7] Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.